Fri, May 2, 11:14 AM (20 days ago)
**Fulgent Genetics, Inc. (FLGT) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** $73.5 million, up 14% YoY, driven by growth in precision diagnostics, anatomic pathology, and BioPharma services. - **Gross Profit:** $28.3 million, up 28% YoY, with a gross margin of 39%. - **Operating Loss:** $19.8 million, improved by $2 million YoY. - **Net Loss:** $11.5 million, improved by $1.9 million YoY. - **Cash Position:** $814.6 million in cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2025. **Segment Performance:** - **Laboratory Services:** Revenue up 14% YoY, with growth in precision diagnostics, anatomic pathology, and BioPharma services. - **Therapeutic Development:** Research and development expenses increased by 29% YoY, driven by clinical studies for FID-007 and FID-022. **Cash Flow:** - **Operating Cash Flow:** $(4.4) million, down from $7.3 million in Q1 2024, due to timing of cash receipts and payments. - **Investing Cash Flow:** $27.7 million, primarily from maturities of marketable securities. - **Financing Cash Flow:** $(11.2) million, primarily for stock repurchases. **Future Outlook and Uncertainties:** - **Growth Strategies:** Focus on expanding testing revenue, improving margins, and entering new markets. - **Uncertainties:** Dependence on a few customers, regulatory approvals for drug candidates, and potential impacts of U.S. trade policies. - **Stock Repurchase:** $141.8 million remaining for future repurchases under the stock repurchase program. **Key Metrics:** - **Revenue Growth:** 14% YoY. - **Gross Margin:** 39%. - **Operating Loss Improvement:** $2 million YoY. - **Cash Position:** $814.6 million. **Trends and Future Operations Impact:** - **Revenue Trends:** Positive growth in precision diagnostics, anatomic pathology, and BioPharma services. - **Operational Trends:** Increased research and development expenses for therapeutic development. - **Future Impact:** Continued investment in clinical trials and laboratory services, with a focus on improving profitability and expanding market reach.